FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

Education Law §6808-b and 8 NYCRR §63.8(b)(1) require every nonresident establishment (pharmacy, manufacturer, wholesaler or outsourcing facility) that ships, mails or delivers prescription drugs or devices to establishments, authorized prescribers or patients in New York to register with the State Education Department. The pharmacy must be licensed and in good standing in its home state, keep readily retrievable records of drugs shipped into New York, and comply with New York controlled-substance law. The application (form OOS 500 P) costs $345 (renewed triennially at $260) and requires a home-state license verification, a sample label with a toll-free number, and a signed letter from the owner and supervising pharmacist acknowledging that New York does not allow compounding for office use. A pharmacy may apply for an exception if it limits New York dispensing to 'isolated transactions' (600 or fewer prescriptions per calendar year). Neither the statute nor §63.8 sets a separate nonresident sterile-compounding permit, an NY-licensed PIC requirement for nonresident pharmacies, or an NABP/VPP inspection requirement.

Isolated-transaction exception (600 or fewer Rx/year) is granted on application under 8 NYCRR §63.8(e); it does not apply to outsourcing facilities. The nysenate.gov copy of §6808-b shows a 2026-05-29 revision and now also covers nonresident pharmacies that participate in 'shared pharmacy services' for NY pharmacies/patients; the application form (Rev. 6/26) adds a signed shared-pharmacy-services acknowledgment. A 2017 bill (S6104) that would have required NABP VPP inspections for nonresident sterile compounders was never enacted. Several third-party guides repeat that VPP requirement as if it were law; it is not in §6808-b or §63.8.

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

The NYS Board of Pharmacy's nonresident pharmacy application requires the owner and supervising pharmacist to sign a letter acknowledging that 'NYS does not allow compounding for office use' and that compounded products will be prepared and dispensed pursuant to patient-specific prescriptions. The Board states that New York has never accepted routine compounding of bulk preparations for office use as the practice of pharmacy and considers it manufacturing. Education Law §6801 defines pharmacy practice as preparing, compounding or dispensing drugs 'on the basis of prescriptions or other legal authority,' and §6802 defines a 'manufacturer' as one who compounds or prepares drugs for distribution or sale to pharmacies or other channels. This matches FDA's view that 503A compounding requires patient-specific prescriptions. Non-patient-specific sterile compounded drugs are the domain of outsourcing facilities registered under Education Law §6808 / §6808-b.

The prohibition is stated as Board policy in the application packet (form revised 6/26) rather than in a single rule section expressly titled 'office use'; no 2025–2026 bill or rule changing this position was found. The form's acknowledgment applies to nonresident pharmacies, so an out-of-state 503A pharmacy registered in NY is bound by it.

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

Education Law §6808-b and 8 NYCRR §63.8(b)(1) include outsourcing facilities located outside New York in the nonresident establishment registration requirement, and §63.8(b)(7) adds conditions for nonresident outsourcing facilities: comply with cGMP (21 CFR parts 210 and 211); be supervised at all times by a pharmacist licensed and registered in New York; submit results of an inspection by FDA, NYSED or an acceptable third party at initial registration and at least annually; and not dispense or distribute any drug pursuant to a prescription unless also registered as a New York pharmacy. The isolated-transaction exception does not apply to nonresident outsourcing facilities (§63.8(e)). Education Law §6808 also requires outsourcing facilities to be under the supervision of a New York-licensed pharmacist and to report the drugs they compounded to the Board every six months.

A patient-specific shipment by a 503B requires it to also hold New York pharmacy registration (§63.8(b)(7)(viii)). §63.8 cites the 2014 edition of 21 CFR 210/211.

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. FDA lists only Colorado, Kentucky and New Hampshire as signatories; New York is not among them. For a non-signing state, FD&C Act §503A(b)(3)(B)(ii) caps a 503A pharmacy's out-of-state distribution of compounded drugs at 5% of its total prescription orders. FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

The NYS Department of Health Bureau of Narcotic Enforcement (BNE) states that the requirement to prescribe a controlled substance in New York is the appropriate practitioner license and a DEA registration, and that there is no separate state controlled substance license for practitioners. Public Health Law licensing from BNE applies to manufacturers, distributors, importers/exporters, institutional dispensers and institutional dispensers limited (Class 3A), researchers and similar entities. New York prescribers still use official NY prescription forms/EPCS and must consult the I-STOP PMP under separate rules.

Page shows 'Revised: September 2026'. A facility that qualifies as an institutional dispenser (e.g. certain clinics/ambulatory surgery settings) needs a BNE license; a private practitioner office does not per this page. NP/PA: the BNE statement covers 'practitioners' generally.

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

Public Health Law Sec. 3343-a(2)(a) states that every practitioner shall consult the prescription monitoring program registry prior to prescribing or dispensing any controlled substance listed on schedule II, III or IV, so the duty applies to each prescription and also to practitioners who dispense. Exceptions include veterinarians, practitioners administering a controlled substance, prescribing for use on the premises of an institutional dispenser, emergency-department prescribing of no more than a 5-day supply, hospice patients, situations where timely access is not reasonably possible and no more than a 5-day supply is given, registry outages, and waivers granted by the Department of Health. A practitioner may authorize a designee to consult the registry. The PMP registry is maintained under the Public Health Law by the NYS Department of Health.

The NY Senate page showed 'Last Updated June 5, 2026'. Testosterone and other anabolic steroids are Schedule III, so they trigger the duty; Schedule V drugs do not. The PDMP TTAC list also cites 10 NYCRR 80.63 and related rules.

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

Education Law 6807(2) limits practitioner dispensing to a 72-hour supply. Exceptions: hospital practice, dispensing at no charge, practices 10 or more miles from a registered pharmacy, college health services, nurse practitioners, medical emergencies, drugs diluted, reconstituted or compounded by the prescriber, allergenic extracts, and oncology or AIDS protocols. Ongoing in-office sales of testosterone, GLP-1s or other chronic therapies fall outside these exceptions.

The 'diluted, reconstituted or compounded by a prescriber' exception is narrow and fact-specific; it is not a general allowance for dispensing compounded products bought from a pharmacy.

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

(1) Full New York licensure and current registration are required to treat patients in New York by telehealth; only occasional consultation with New York physicians is exempt (Educ. Law 6526(3), per NYSED telepractice guidance quoted by CCHP). (2) 10 NYCRR 80.63(d) bars prescribing a controlled substance before an in-person medical evaluation by the prescriber, but 80.63(e)(4), amended effective 5/21/2025, allows prescribing through telemedicine or telehealth consistent with state law and DEA rules, so the state rule now defers to the federal Ryan Haight/DEA telemedicine framework. (3) Other controlled-substance rules apply equally to telehealth, including checking the PMP registry within 24 hours before prescribing Schedule II-IV drugs (80.63(c)); no separate New York telehealth limit on testosterone was found. (4) IMLC: not a member (legislation introduced 3/4/2026).

Change: the long-standing NY in-person evaluation rule (80.63(d)) gained a telehealth exception (80.63(e)(4)) effective 2025-05-21 (NY State Register Vol. XLVII, Issue 20). In practice the in-person question now turns on federal DEA telemedicine rules. IMLC legislation introduced 2026 (IMLC map status date 3/4/2026).

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

The NYSED Office of the Professions (updated September 2026) states that in most cases New York law requires an RN to execute medical regimens ordered for a specific patient by a physician or other qualified practitioner who has examined the patient, and that RNs may not follow orders or protocols that let them diagnose or choose treatment. Non-patient-specific orders are allowed only for listed services (immunizations, anaphylaxis and opioid-overdose treatment, specified tests and screenings, certain emergency and newborn services), which do not include neuromodulators or fillers. LPNs work under RN or practitioner direction.

Page dated 'September 2026' (recorded as 2026-09-01); it does not quote statute section numbers. No NYSED statement specific to cosmetic injectables was found on the RN FAQ or practice-issues pages.

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

NYSED's guidance says RNs generally must execute regimens ordered for a specific patient by a practitioner who has examined the patient, and the short list of services that can be delivered under non-patient-specific orders and protocols does not include IV hydration, vitamin or NAD+ infusions. A 2025 law-firm review adds that RNs and LPNs with formal IV training and competency may administer IV therapy in med spas, LPNs only under supervision by an RN, NP or physician available to intervene, and that medical assistants may not. NYSED also publishes Board of Nursing guidance on IV therapy by LPNs.

No NY IV-hydration-specific board statement was found. The LPN IV guidance documents are listed on the practice-issues page but were not individually reviewed.

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

Permit Health's 2025 guide classifies New York as strict, citing N.Y. Educ. Law §6522, Pub. Health Law §2806 and cases such as People v. Woodbury Dermatological Inst. (1908) and Stern v. Flynn (1936). MedPath Compliance (reviewed 2026-06-20) also rates New York strict and reports a pending bill (S8442/A9012) to limit MSO control and a budget expansion of health-transaction review.

Statutes not fetched.

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

New York has no laser-technician licence. Under NYSED guidance, an RN performing a laser treatment would need a patient-specific order from a physician, PA or NP who examined the patient. Whether estheticians or unlicensed technicians may perform laser hair removal in New York could not be confirmed from official sources (the Department of State appearance-enhancement pages blocked automated access); a 2026 training-provider guide says laser hair removal has no dedicated licence in New York and that a licensing bill (S6231A) is pending.

Check with NYSED Office of the Professions (physicians/nursing) and the NY Department of State Division of Licensing Services.

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

Under Public Health Law Article 5, Title V, the Wadsworth Center's Clinical Laboratory Evaluation Program (CLEP) oversees clinical laboratories and states that 'any laboratory seeking to test New York State specimens must obtain CLEP approval.' New York is a CLIA-exempt state: the state permit program stands in for CLIA for New York labs. CLEP also keeps a database of approved labs and approved laboratory-developed tests. Physician office labs in New York go through a separate program (POLEP).

Out-of-state labs: yes (permit needed to accept NY specimens). New York also restricts direct-access testing (see that topic).

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

Amendments to the Public Health Law effective September 24, 2002 let clinical labs holding the appropriate NY permit offer direct access testing, limited to 'tests for which a Federal Food and Drug Administration (FDA) approved test kit or collection device is available over-the-counter (OTC) without a prescription, and for tests for the same purpose.' The FDA OTC database defines the eligible list. Limited Service Laboratories may not offer direct access testing, and any lab testing NY specimens needs a NY permit.

Consumer panels without an FDA OTC counterpart need a practitioner order in New York.

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

Compilations of state stem-cell laws from 2024 to 2026 list about a dozen states with specific laws (California, Florida, Georgia, Mississippi, Nevada, North Carolina, Tennessee, Texas, Utah, Vermont, Washington and Wyoming), plus Montana's general experimental-treatment law and Kansas's state stem cell center. New York is not among them. Without a state-specific law, regenerative products are governed by federal FDA rules plus the state's general medical practice, advertising and consumer-protection laws, enforced by its medical board. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

The finding of no law rests on multi-state compilations (a commercial one from Aug 2026 and a peer-reviewed one from Feb 2024, which is older than 2 years) and targeted searches, not a statute-by-statute review, and neither compilation is exhaustive. General Right to Try laws for terminal patients, where they exist, were not reviewed here.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

ECL §37-0117 bars selling cosmetic products with 1,4-dioxane above 10 ppm (since Dec 31, 2022) and personal care products above 2 ppm (Dec 31, 2022) and then 1 ppm (Dec 31, 2023). It also bans cosmetic or personal care products containing mercury beyond trace amounts, and the thresholds are reviewed every two years from May 1, 2025. GBL §399-aaaaa bars importing for profit or selling cosmetics developed with animal testing conducted after its effective date, with exceptions; the Attorney General may seek penalties of up to $5,000 plus $1,000 per day.

Pending: Assembly Bill 8585 would ban cosmetics with intentionally added PFAS (proposed effective Jan 1, 2029). Not enacted as of the March 2026 compilation. The animal-testing law's effective date was not shown on the statute page (2023 per compilation). Federal MoCRA and FDA cosmetic and OTC sunscreen rules apply in every state.